<DOC>
	<DOCNO>NCT00434148</DOCNO>
	<brief_summary>This study evaluate safety efficacy two different dos Pasireotide patient de novo recurrent/persistent Cushing 's Disease .</brief_summary>
	<brief_title>Safety Efficacy Different Dose Levels Pasireotide Patients With de Novo , Persistent Recurrent Cushing 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Inclusion criterion 18 year great Confirmed diagnosis ACTHdependent Cushing 's disease Not consider candidate pituitary surgery Exclusion criterion History pituitary irradiation last 10 year Cushing 's syndrome cause pituitary tumor Patients active malignant disease ( cancer ) last 5 year Women pregnant lactate Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cushing 's Disease</keyword>
	<keyword>pasireotide</keyword>
	<keyword>SOM230</keyword>
</DOC>